Your browser doesn't support javascript.
loading
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
Furst, Daniel E; Jaworski, Janusz; Wojciechowski, Rafal; Wiland, Piotr; Dudek, Anna; Krogulec, Marek; Jeka, Slawomir; Zielinska, Agnieszka; Trefler, Jakub; Bartnicka-Maslowska, Katarzyna; Krajewska-Wlodarczyk, Magdalena; Klimiuk, Piotr A; Lee, Sang Joon; Kim, Sung Hyun; Bae, Yun Ju; Yang, Go Eun; Yoo, Jae Kyoung; Kay, Jonathan; Keystone, Edward.
Afiliación
  • Furst DE; Division of Rheumatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA.
  • Jaworski J; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Wojciechowski R; Department of Medicine, University of Florence, Florence, Italy.
  • Wiland P; Department of Rheumatology, Reumatika-Centrum Reumatologii, Warsaw.
  • Dudek A; Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2, Bydgoszcz.
  • Krogulec M; Department of Rheumatology and Internal Diseases, Medical University, Wroclaw.
  • Jeka S; Department of Rheumatology, Centrum Medyczne AMED, Warsaw.
  • Zielinska A; Rheumatology Clinic, NZOZ Lecznica MAK-MED, Nadarzyn.
  • Trefler J; Department of Rheumatology and Connective Tissue Diseases, Nasz Lekarz Przychodnie Medyczne, Torun.
  • Bartnicka-Maslowska K; Medycyna Kliniczna.
  • Krajewska-Wlodarczyk M; Reuma Centrum, Warsaw.
  • Klimiuk PA; Department of Rheumatology, Centrum Medyczne Amed, Lódz.
  • Lee SJ; Department of Internal Medicine, University of Warmia and Mazury, Olsztyn.
  • Kim SH; Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland.
  • Bae YJ; Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea.
  • Yang GE; Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea.
  • Yoo JK; Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea.
  • Kay J; Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea.
  • Keystone E; Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea.
Rheumatology (Oxford) ; 61(4): 1385-1395, 2022 04 11.
Article en En | MEDLINE | ID: mdl-34142111
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Biosimilares Farmacéuticos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Biosimilares Farmacéuticos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Canadá